| 1 |
Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection[J]. Liver International,2013,33(S1):14-22.
|
| 2 |
McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796[J]. Antimicrob Agents Chem,2009,53(5):2129-2132.
|
| 3 |
Kukolj G, Benhamou Y, Manns MP, et al. 954 BI 201335, a potent HCVNS3 protease inhibitor, in treatment-naive and-experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain[J]. J Hepatol,2009,50:S347.
|
| 4 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol,2014,60(2):392-420.
|
| 5 |
Elazar M, Cheong KH, Liu P, et al. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication[J]. J Virol,2003,77(10):6055-6061.
|
| 6 |
Polyak SJ, Khabar KSA, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response[J]. J Virol,2001,75(13):6095-6106.
|
| 7 |
Lee C. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy[J]. Arch Pharm Res,2011,34(9):1403-1407.
|
| 8 |
Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1[J]. N Engl J Med,2012,366(3):216-224.
|
| 9 |
Everson GT, Sims KD, Rodriguez-Torres M, et al. Interim analysis of an interferon (INF)-and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients[J]. J Gastroenterol Hepatol,2013,28:154.
|
| 10 |
Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885[J]. Antimicrob Agents Chem,2013,57(12):6333-6340.
|
| 11 |
Vince B, Hill JM, Lawitz EJ, et al. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4[J]. J Hepatol,2014,60(5):920-927.
|
| 12 |
Lalezari J, Agarwal K, Dusheiko G, et al. Dose-ranging trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infectio[R]. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. 2011.
|
| 13 |
Lalezari J, Farrell G, Shah P, et al. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: Phase 1 efficacy and safety[R]. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 2012.
|
| 14 |
Targett-Adams P, Graham E JS, Middleton J, et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action[J]. J Virol,2011,85(13):6353-6368.
|
| 15 |
Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect[J]. Nature,2010, 465(7294):96-100.
|
| 16 |
Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system[J]. Antimicrob Agents Chem,2010,54(9):3641-3650.
|
| 17 |
Vince B, Lawitz E, Searle S, et al. Novel NS5A inhibitor ACH-2928 Phase I results in HCV GT-1 patients[J]. J Hepatol,2012,56(2):S480-S481.
|
| 18 |
Garcia-Rivera J, Chatterji U, Gallay P. Cyclophilin inhibitor alisporivir (ALV) combinations with direct acting antivirals reveal strong synergistic anti-HCV effects[J]. J Hepatol,2013,58(S1):S469.
|
| 19 |
Spreen W, Wilfret DA, Bechtel J, et al. GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic genotype 1 infection; results from a first time in human (FTIH) single and repeat dose study[R]. 62th Annual Meeting of the American Association for the Study of Liver Diseases. 2011:400A-401A.
|
| 20 |
Bryant A, Bowman D, Olle B, et al. Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C[R]. Jennifer Levin,2012.
|
| 21 |
Cheng G, Yu M, Peng B, et al. 1191 GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier[J]. J Hepatol,2013, 58(S1):S484-S485.
|
| 22 |
Information T. Gilead Sciences Phase 2 Study of SOF + GS-5816 in treatment naive subjects with chronic HCV[R]. Bone & Cancer Foundation,2013.
|
| 23 |
Sciences G. Gilead reports interim data from Phase 2 LONESTAR study[R]. Foster City, CA: Gilead Sciences, 2013.
|
| 24 |
Delang L, Neyts J, Vliegen I, et al. Hepatitis C Virus-Specific Directly Acting Antiviral Drugs[J]. Curr Top Microbiol Immunol,2013,369:289-320.
|
| 25 |
Hanoulle X, Verdegem D, Badillo A, et al. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded[J]. Biochem Bioph Res Co,2009,381(4):634-638.
|
| 26 |
Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus[J]. Antimicrob Agents Chem,2012,56(6):3359-3368.
|
| 27 |
Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment[J]. J Virol,2013,87(3):1544-1553.
|
| 28 |
Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors[J]. Clin Liver Dis,2011,15(3):611-626.
|
| 29 |
Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C[J]. J Hepatol,2013,59(2):375-382.
|
| 30 |
Walker J, Crosby R, Wang A, et al. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A[J]. Antimicrob Agents Chem,2014,58(1):38-47.
|
| 31 |
McCarville JF, Chapron C, LaColla M, et al. Hepatitis C Virus NS5A inhibitor IDX719 demonstrates potent, pan-genotypic activity in preclinical and clinical studies[J]. Hepatol Int,2013, 10:S330.
|
| 32 |
Gane E, Foster GR, Cianciara J, et al. 2003 antiviral activity pharmacokinetics ,and tolerability of azd7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients[J]. J Hepatol,2010,52:S464.
|
| 33 |
Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients[J]. Virol J,2013,10:355.
|
| 34 |
Wadood A, Riaz M, Jamal S B, et al. Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease[J]. Bioinformation,2013,9(6):309.
|
| 35 |
Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors[J]. Expert Opin Pharmacother,2013,14(9):1161-1170.
|
| 36 |
Zhou XJ, Vince B, Hill J, et al. Pharmacokinetics and pharmacodynamics of IDX719, a pan-genotypic HCV NS5A inhibitor in genotype 1, 2, 3 or 4 HCV-infected subjects[R]. Asian Pacific Association for the Study of the Liver,2013:6-10.
|
| 37 |
Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era[J]. Curr Opin Gastroen,2014,30(3):217-222.
|
| 38 |
World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection[R]. World Health Organization, 2014.
|